Allergen Ingredients TRIZ Cases

Repeated skin allergen application with occlusive patch monitoring promotes immune tolerance while lowering systemic reaction risk.

Peptide-coated bead assays map cow's milk epitopes to diagnose CMA, predict tolerance, and monitor allergic response with less sample.

Purified and recombinant Cupressaceae GRP allergens improve diagnosis of pollen-food cross-reactivity and help identify severe peach allergy risk.

By fully complexing peanut allergens with aluminum, this composition reduces systemic allergic reactions while preserving IgG-driven desensitization.

Mucoadhesive nanofibers and bacterial carriers protect oral mRNA from enzyme degradation and improve delivery for antigen-specific immune tolerance.

Two Ara h 2 peptide epitopes on a solid support improve peanut allergy diagnosis and tolerance monitoring with higher specificity.

Synthetic consensus allergens combine sequences from multiple proteins to desensitize cross-reactive allergies with one broader vaccine approach.

Aqueous extraction with anion exchange and reverse phase chromatography controls Ara h 1, 2, 3, and 6 ratios while limiting aggregates.

Implantable devices co-deliver allergens and AhR agonists to stimulate TGF-β and IL-10, accelerating immune tolerance.

Non-daily maintenance dosing in peanut oral immunotherapy sustains desensitization while easing treatment burden and safety concerns.

Disease-specific antigens are delivered to antigen-presenting cells to induce regulatory T cells without broad immunosuppression or infection risk.

Controlled allergen application on skin uses monitored inflammation to build immune tolerance without adjuvants or routine clinical supervision.

Secretory component shields dimeric IgA-antigen complexes from GI degradation while reducing allergic symptoms.

Peanut immunotherapy uses IgE thresholds to select candidates, tailor monitoring, and reduce adverse reactions during treatment.

Isolating the Cor a 9 allergen protein enables precise detection of hazelnut-induced systemic allergic reactions in patients.

Dry heat sterilization removes replication viable organisms from blended food allergens while maintaining protein structure.

Segmented cockroach allergen peptides modulate specific T cell responses, resolving unaddressed immunopathology in allergic asthma treatments.

Patsnap Eureka analyzes a sesame nsLTP polypeptide immobilized on a solid phase carrier to detect specific IgG and IgE antibodies in patient samples.

Conjugating the IgE Cε3 domain with CRM197 induces protective antibodies that reduce circulating IgE levels and prevent anaphylaxis without adverse reactions.

Baby food products deliver defined allergenic proteins combined with prebiotics to establish long-term immune tolerance and reduce allergy prevalence.

Patsnap Eureka analyzes how purified Equ c s allergen components resolve cross-reactivity issues by distinguishing specific IgE responses from false positives.

Non-aqueous solvent precipitates allergen particles in tissue, resolving unpredictable tolerance induction from traditional aqueous methods.

Conjugating antigens to liver-targeting moieties directs them to hepatocytes, resolving insufficient tolerance induction in autoimmune treatments.

Anti-Ara h 2 antibodies neutralize peanut allergen Ara h 2, preventing IgE binding and anaphylaxis risk during oral immunotherapy.

Segmented pellets with stomach-labile coatings deliver allergens to the gut immune system, reducing false-positive reactions from oral exposure.

A segmented liquid extraction process purifies allergen extracts by sequentially removing lipids and low molecular weight contaminants.

Chitosan and hyaluronic acid bilayers enable controlled protein release through the buccal mucosa, bypassing gastrointestinal degradation.

Acidified ultrafiltration separates flavonoid glycosides from grass pollen extracts, eliminating in vitro genotoxicity while preserving allergen immunogenicity.

Epicutaneous allergen patches bypass injection risks by inducing regulatory T cells, preventing multiple childhood allergies.

Linking mutated Par j 1 and Par j 2 sequences reduces IgE reactivity by 41% and prevents severe side effects in allergic disease immunotherapy.

Dialdehyde crosslinks protein antigens and mannan into a covalent immunogenic complex that stimulates immune responses.

Classifying allergic patients via allergen-specific T cell reactivity measurements to enable customized immunotherapy compositions.

Site-directed mutagenesis creates Mal d 1 variants that lower IgE binding while preserving protective IgG induction to treat pollen and food allergies.

Targeted mutations in the Bet v 1a IgE-binding region reduce IgE reactivity while preserving T-cell epitopes for effective pollen-food syndrome therapy.

Granular formulations combine trehalose, hypromellose, mannitol, and stearic acid to mask taste while maintaining protein stability.

Isolating purified Equ c 15k allergen proteins resolves insufficient diagnostic sensitivity caused by suboptimal natural extract potency.

Engineered recombinant Equ c 1 polypeptides minimize anaphylactic side effects by reducing IgE-binding epitopes while preserving immunogenic potential.

Administers allergens alongside biotic agents to shift Th1 over Th2 responses, reducing severe allergic reactions during treatment.

Measuring Th2a cell frequencies provides accurate immune response monitoring, resolving variable efficacy and long therapy duration constraints.

Specific probiotic strains modulate the gut microbiome to induce long-term tolerance, addressing the short-term desensitization limits of oral immunotherapy.

Fluorescent probe detects histamine release from buccal cells to identify allergic components in food mixtures.

Recombinant Can f 4 allergen resolves diagnostic sensitivity limits from complex natural dog dander extracts by providing pure, standardized protein.

A mucoadhesive sublingual film delivers allergen extracts through a dissolving polymer matrix.

Segmenting the Bet v 1 allergen into contiguous overlapping peptides reduces treatment duration and side effects by minimizing IgE binding.

An IL-4R antagonist blocks IgE production during subcutaneous immunotherapy, reducing severe hypersensitivity reactions while maintaining efficacy.

Dual chemical modification reduces allergenic activity by 227-folds, enabling safe immunotherapy induction without severe side effects.

A pre-diluted allergen kit system simplifies immunotherapy delivery through sequential dilution and standardized packaging.

Reduction and cross-linking reduce IgE binding in allergens, enabling safer desensitization without compromising therapeutic efficacy.

A rapid dose escalation protocol increases peanut allergen dosage from 5 mg to 200 mg within 4 to 9 weeks.

A three-dimensional hydrogel microchip immobilizes allergens to enable simultaneous quantitative determination of immunoglobulins E and G.